Searching across hundreds of databases
Ischemic stroke is a leading cause of adult disability with no pharmacological treatments to promote the recovery of lost function. Neutralizing antibodies against the neurite outgrowth inhibitor Nogo-A have emerged as a promising treatment for subacute and chronic stroke in animal models; however, whether anti-Nogo-A treatment affects poststroke neurogenesis remains poorly understood. In this study, we confirmed expression of Nogo-A by neuroblasts in the adult rat subventricular zone (SVZ), a major neurogenic niche; however, we found no evidence that Nogo-A was expressed at the surface of these cells. In vitro migration assays demonstrated that Nogo-A signaling induced a modest reduction in neuroblast migration speed, while anti-Nogo-A antibodies had no effect on motility properties. Using a permanent distal middle cerebral artery occlusion model of cortical stroke, we found that the number of proliferating cells in the SVZ was unaffected in response to stroke, while neuroblast mobilization from the SVZ toward the stroke lesion correlated positively with lesion size. However, we found no evidence that proliferation or neuroblast mobilization were affected by anti-Nogo-A antibody treatment. Our results suggest that the SVZ is not a therapeutic target of anti-Nogo-A immunotherapy, and contribute to our understanding of the SVZ response to cortical stroke.
Pubmed ID: 28789474 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets GOAT ANTI HUMAN IgG F(ab')2:BIOTIN
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis unknown targets Mouse IgG1 (??1)
View all literature mentionsThis unknown targets Mouse IgG, Fc? Subclass 2a Specific
View all literature mentionsThis unknown targets Mouse IgG2a (??2a)
View all literature mentionsThis unknown targets Nogo Receptor
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis polyclonal targets GFAP
View all literature mentionsThis monoclonal targets Neuronal Class III beta-Tubulin (TUJ1) Purified
View all literature mentionsThis monoclonal targets BrdU
View all literature mentionsThis polyclonal targets Calnexin
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets GOAT ANTI HUMAN IgG F(ab')2:BIOTIN
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis unknown targets Mouse IgG1 (??1)
View all literature mentionsThis unknown targets Mouse IgG, Fc? Subclass 2a Specific
View all literature mentionsThis unknown targets Mouse IgG2a (??2a)
View all literature mentionsThis unknown targets Nogo Receptor
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis polyclonal targets GFAP
View all literature mentionsThis monoclonal targets Neuronal Class III beta-Tubulin (TUJ1) Purified
View all literature mentionsThis monoclonal targets BrdU
View all literature mentionsThis unknown targets IgG
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis unknown targets Mouse IgG1 (??1)
View all literature mentionsThis polyclonal targets GOAT ANTI HUMAN IgG F(ab')2:BIOTIN
View all literature mentionsThis unknown targets Mouse IgG, Fc? Subclass 2a Specific
View all literature mentionsThis polyclonal targets GFAP
View all literature mentionsThis unknown targets Nogo Receptor
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis unknown targets Mouse IgG2a (??2a)
View all literature mentionsThis polyclonal targets Calnexin
View all literature mentionsThis polyclonal targets Calnexin
View all literature mentionsThis monoclonal targets Neuronal Class III beta-Tubulin (TUJ1) Purified
View all literature mentionsThis monoclonal targets BrdU
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
